Loading...
ROCO
3218
Market cap351mUSD
Jul 09, Last price  
141.00TWD
1D
0.00%
1Q
8.46%
Jan 2017
603.94%
IPO
326.63%
Name

Universal Vision Biotechnology Co Ltd

Chart & Performance

D1W1MN
ROCO:3218 chart
P/E
10.81
P/S
2.68
EPS
13.04
Div Yield, %
5.32%
Shrs. gr., 5y
0.19%
Rev. gr., 5y
15.41%
Revenues
4.20b
-0.57%
1,418,979,0002,053,141,0002,631,801,0003,494,057,0004,082,256,0004,228,302,0004,204,086,000
Net income
1.04b
-2.07%
238,005,000483,214,000595,428,000850,533,0001,045,094,0001,064,721,0001,042,637,000
CFO
1.67b
-0.34%
419,182,000827,081,000911,771,0001,268,168,0001,553,592,0001,672,066,0001,666,439,000
Dividend
Mar 26, 20257.5 TWD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Universal Vision Biotechnology Co., Ltd., established in 1992 and based in Taipei, Taiwan, manages a network of eye care clinics across both Taiwan and China. The company delivers a comprehensive range of ophthalmic services, encompassing advanced surgical interventions and treatments for various ocular conditions. Its surgical specialties include laser vision correction for common refractive errors such as myopia (nearsightedness), hyperopia (farsightedness), astigmatism, and presbyopia (age-related vision decline). They also perform intraocular lens procedures for presbyopia and cataracts, employing advanced techniques like phacoemulsification and femtosecond laser surgery. Beyond surgical solutions, Universal Vision addresses a wide spectrum of eye health concerns, offering services for myopia control, dry eye syndrome, retinal detachment, macular degeneration, strabismus (crossed eyes), amblyopia (lazy eye), and numerous other ophthalmic ailments. The company further provides a diverse array of vision products and optical aids, including various eyeglass frames, specialized multifocal and progressive lenses for myopia and presbyopia, sunglasses, orthokeratology, rigid gas permeable lenses, and both conventional and colored contact lenses. Nutritional eye supplements are also available. Additional offerings include oculoplastic and micro cosmetic eye surgery, alongside bespoke aesthetic medicine consultations. Furthermore, Universal Vision engages in optometric services, hospital administration, technical advisory roles, and the distribution and rental of medical equipment.
IPO date
Jan 29, 2004
Employees
Domiciled in
TW
Incorporated in
TW

Valuation

Title
TWD in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT